Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Frequency rhythmic electrical modulation system (FREMS) to alleviate painful diabetic peripheral neuropathy : a pilot, randomised controlled trial (The FREMSTOP study)

Tools
- Tools
+ Tools

Crasto, W., Altaf, Q -A., Selvaraj, D. R., Jack, B., Patel, Vinod, Nawaz, S., Murthy, N., Sukumar, Nithya, Saravanan, Ponnusamy and Tahrani, A. A. (2022) Frequency rhythmic electrical modulation system (FREMS) to alleviate painful diabetic peripheral neuropathy : a pilot, randomised controlled trial (The FREMSTOP study). Diabetic medicine : a journal of the British Diabetic Association, 39 (3). e14710. doi:10.1111/dme.14710

Research output not available from this repository, contact author.
Official URL: http://dx.doi.org/10.1111/dme.14710

Request Changes to record.

Abstract

Frequency Rhythmic Electrical Modulated system (FREMS) is a non-invasive treatment for chronic pain conditions but its place in the treatment algorithm for painful diabetic peripheral neuropathy (PDPN) is unknown. A pilot, open-label randomised controlled trial in individuals with PDPN inadequately controlled on at least dual neuropathic pain treatments recruited from primary and secondary care. Participants were randomised 1:1 to FREMS+usual care(n=13) vs. usual care(n=12). Primary outcome was change from baseline in perceived pain (assessed by visual analogue scale) at 12 weeks between treatment groups. Of 25 participants, 14(56%) were men and 21(84%) were White Europeans. Median(IQR) age and duration of diabetes were 64(56,68) and 14(10,20) years, respectively. At 12 weeks, FREMS showed improvements in perceived pain compared to baseline, although the change was not statistically significant from control group [-4.0(-5.0,0.4) vs 0(-0.3,0.7), p=0.087]. There were significant improvements in pain with FREMS, assessed by McGill Pain questionnaire (p=0.042) and Douleur neuropathique-4 questionnaire (p=0.042). More patients on FREMS had greater than 30 percent reductions in perceived pain compared to controls [7/13(54%) vs. 0/12(0%), p=0.042] and significant improvements in Patient Global Impression of Change (p=0.005). FREMS intervention had moderate benefits in quality of life, sleep, depression and pain medication use, but these were not statistically significant. FREMS might be used to treat individuals with PDPN inadequately controlled on two classes of neuropathic pain medications and is associated with improvements in pain severity and perceived impact of treatment. A larger, appropriately designed trial assessing its impact in this population is needed. [Abstract copyright: This article is protected by copyright. All rights reserved.]

Item Type: Journal Article
Divisions: Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences
Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences > Population, Evidence & Technologies (PET)
Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School
SWORD Depositor: Library Publications Router
Journal or Publication Title: Diabetic medicine : a journal of the British Diabetic Association
Publisher: Wiley-Blackwell Publishing Ltd.
ISSN: 0742-3071
Official Date: March 2022
Dates:
DateEvent
March 2022Published
4 October 2021Available
29 September 2021Accepted
Volume: 39
Number: 3
Article Number: e14710
DOI: 10.1111/dme.14710
Status: Peer Reviewed
Publication Status: Published
Publisher Statement: "This is the peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited."
Access rights to Published version: Restricted or Subscription Access
Copyright Holders: © 2021 Diabetes UK

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item
twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us